Alkhaffaf Bilal, Glenny Anne-Marie, Blazeby Jane M, Williamson Paula, Bruce Iain A
Department of Oesophago-Gastric Surgery, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK.
Trials. 2017 Aug 9;18(1):370. doi: 10.1186/s13063-017-2100-7.
Gastric cancer is one of the leading causes of cancer-related deaths worldwide. Whilst surgery is the mainstay of curative treatment, it is associated with significant risks. Surgical strategies for treating gastric cancer should be based on evidence from systematic reviews of well-designed randomised controlled trials. However, inconsistencies in the reporting of outcomes from these trials makes evidence synthesis unreliable. We present a protocol for an international consensus study to develop a standardised set of outcomes and measurement tools - a 'core outcome set' (COS) - to be used by all future trials examining therapeutic surgical interventions for gastric cancer. The GASTROS study aims to standardise the reporting of outcomes in gastric cancer surgery trials through an international consensus process of key stakeholders including health care professionals and patients.
The first of three stages in the study will identify a 'long-list' of potentially important outcomes to be prioritised. These will be extracted from a systematic review of relevant academic literature and patient interviews. Stage 2 will comprise an eDelphi survey which will consider the views of patients, nurse specialists and surgeons to prioritise the most important outcomes. A meeting of stakeholder representatives will ratify the COS. Stage 3 will focus on identifying appropriate instruments to measure the prioritised outcomes by means of quality assessment of available measurement instruments and stakeholder consultation.
This study aims to standardise the reporting of outcomes in future trials examining therapeutic surgical interventions for gastric cancer. It is anticipated that standardisation of outcome reporting in these surgical effectiveness trials will enhance the evidence base for clinical practice. Highlighting outcomes of greatest importance to patients will ensure that their perspectives are central to research in this field.
胃癌是全球癌症相关死亡的主要原因之一。虽然手术是根治性治疗的主要手段,但它伴随着重大风险。治疗胃癌的手术策略应基于精心设计的随机对照试验的系统评价证据。然而,这些试验结果报告的不一致性使得证据合成不可靠。我们提出了一项国际共识研究方案,以制定一套标准化的结局和测量工具——一个“核心结局集”(COS),供未来所有研究胃癌治疗性手术干预的试验使用。GASTROS研究旨在通过包括医疗保健专业人员和患者在内的关键利益相关者的国际共识过程,规范胃癌手术试验结局的报告。
该研究三个阶段中的第一阶段将确定一份有待优先排序的潜在重要结局的“长名单”。这些结局将从相关学术文献的系统评价和患者访谈中提取。第二阶段将包括一项电子德尔菲调查,该调查将考虑患者、护士专家和外科医生的意见,以对最重要的结局进行优先排序。利益相关者代表会议将批准核心结局集。第三阶段将专注于通过对现有测量工具的质量评估和利益相关者咨询,确定测量优先结局的合适工具。
本研究旨在规范未来研究胃癌治疗性手术干预的试验中结局的报告。预计这些手术疗效试验中结局报告的标准化将加强临床实践的证据基础。突出对患者最重要的结局将确保他们的观点成为该领域研究的核心。